Challenges and new strategies for therapeutic peptide delivery to the CNS

Therapeutic Delivery

Volumn 6, Issue 7, 2015, Pages 841-853

  McGowan, Jeremy W D ^a   Bidwell, Gene L ^a   Vig, Parminder J S ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PENETRATING PEPTIDE; DRUG CARRIER; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PEPTIDE DERIVATIVE; POLYPEPTIDE; CENTRAL NERVOUS SYSTEM AGENTS; EXCIPIENT; PEPTIDE;

BLOOD BRAIN BARRIER; CELL PERMEABILIZATION; CENTRAL NERVOUS SYSTEM; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; ANIMAL; CHEMISTRY; DRUG ADMINISTRATION ROUTE; DRUG STABILITY; HUMAN; MEDICINAL CHEMISTRY; METABOLISM; PERMEABILITY; PHARMACEUTICS; PROCEDURES; PROTEIN STABILITY; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELL-PENETRATING PEPTIDES; CENTRAL NERVOUS SYSTEM AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG STABILITY; EXCIPIENTS; HUMANS; NANOPARTICLES; PEPTIDES; PERMEABILITY; PROTEIN STABILITY; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84938367332     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.15.30     Document Type: Review

References (68)

1. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Meth. 44(1), 235-249 (2000).
2. Bidwell GL, Raucher D. Therapeutic peptides for cancer therapy. Part I-peptide inhibitors of signal transduction cascades. Exp. Opin. Drug Deliv. 6(10), 1033-1047 (2009).
3. Bidwell GL. Peptides for cancer therapy: a drug-development opportunity and a drug-delivery challenge. Ther. Deliv. 3(5), 609-621 (2012).
4. Hearst SM, Shao Q, Lopez M, Raucher D, Vig PJ. The design and delivery of a PKA inhibitory polypeptide to treat SCA1. J. Neurochem. 131(1), 101-114 (2014).
5. Bicker J, Alves G, Fortuna A, Falcao A. Blood-brain barrier models and their relevance for a successful development of cns drug delivery systems: a review. Eur. J. Pharm. Biopharm. 87(3), 409-432 (2014).
6. Agarwal N, Lippmann ES, Shusta EV. Identification and expression profiling of blood-brain barrier membrane proteins. J. Neurochem. 112(3), 625-635 (2010).
7. Abraham MH. The factors that influence permeation across the blood-brain barrier. Eur. J. Med. Chem. 39(3), 235-240 (2004).
8. Upadhyay RK. Drug delivery systems, cns protection, and the blood brain barrier. Biomed. Res. Int. 2014, 869269 (2014).
9. Salameh TS, Banks WA. Delivery of therapeutic peptides and proteins to the cns. Adv. Pharmacol. 71, 277-299 (2014).
10. Bockenhoff A, Cramer S, Wolte P et al. Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase a. J. Neurosci. 34(9), 3122-3129 (2014).
11. Pardridge WM. Drug transport across the blood-brain barrier. J. Cereb. Blood. Flow. Metab. 32(11), 1959-1972 (2012).
12. Boado RJ, Lu JZ, Hui EK, Sumbria RK, Pardridge WM. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase A and a monoclonal antibody against the human insulin receptor. Biotech. Bioeng. 110(5), 1456-1465 (2013).
13. Sumbria RK, Boado RJ, Pardridge WM. Brain protection from stroke with intravenous tnfalpha decoy receptor-trojan horse fusion protein. J. Cereb. Blood. Flow. Metab. 32(10), 1933-1938 (2012).
14. Ponka P, Lok CN. The transferrin receptor: Role in health and disease. Int. J. Biochem. Cell. Biol. 31(10), 1111-1137 (1999).
15. Sumbria RK, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Mol. Pharm. 10(4), 1425-1431 (2013).
16. Farrington GK, Caram-Salas N, Haqqani AS et al. A novel platform for engineering blood-brain barrier-crossing bispecific biologics. FASEB J. 28(11), 4764-4778 (2014).
17. Regina A, Demeule M, Tripathy S et al. Ang4043, a novel brain-penetrant peptide-mab conjugate, is efficacious against her2-positive intracranial tumors in mice. Mol. Cancer. Ther. 14(1), 129-140 (2015).
18. Georgieva JV, Hoekstra D, Zuhorn IS. Smuggling drugs into the brain: an overview of ligands targeting transcytosis for drug delivery across the blood-brain barrier. Pharmaceutics 6(4), 557-583 (2014).
19. Boado RJ, Hui EK, Lu JZ, Pardridge WM. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconj. Chem. 24(1), 97-104 (2013).
20. Cornford EM, Hyman S. Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx 2(1), 27-43 (2005).
21. Pinzon-Daza ML, Salaroglio IC, Kopecka J et al. The crosstalk between canonical and non-canonical Wnt-dependent pathways regulates p-glycoprotein expression in human blood-brain barrier cells. J. Cereb. Blood Flow Metab. 34(8), 1258-1269 (2014).
22. Liu JS, Wang JH, Zhou J et al. Enhanced brain delivery of lamotrigine with pluronic((r)) p123-based nanocarrier. Int. J. Nanomed. 9, 3923-3935 (2014).
23. Beccaria K, Canney M, Goldwirt L et al. Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits. J. Neurosurg. 119(4), 887-898 (2013).
24. Chen H, Chen CC, Acosta C, Wu SY, Sun T, Konofagou EE. A new brain drug delivery strategy: focused ultrasoundenhanced intranasal drug delivery. PLoS ONE 9(10), e108880 (2014).
25. Fasano A, Fiorentini C, Donelli G et al. Zonula occludens toxin modulates tight junctions through protein kinase c-dependent actin reorganization, in vitro. J. Clin. Invest. 96(2), 710-720 (1995).
26. Lu R, Wang W, Uzzau S, Vigorito R, Zielke HR, Fasano A. Affinity purification and partial characterization of the zonulin/zonula occludens toxin (Zot) receptor from human brain. J. Neurochem. 74(1), 320-326 (2000).
27. Menon D, Karyekar CS, Fasano A, Lu R, Eddington ND. Enhancement of brain distribution of anticancer agents using deltag, the 12 kDa active fragment of Zot. Int. J. Pharm. 306(1-2), 122-131 (2005).
28. Kim DG, Bynoe MS. A2a adenosine receptor regulates the human blood-brain barrier permeability. Mol. Neurobiol. (2014) (Epub ahead of print).
29. Sarkar G, Curran GL, Sarkaria JN, Lowe VJ, Jenkins RB. Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain. PLoS ONE 9(5), e97655 (2014).
30. Foley CP, Rubin DG, Santillan A et al. Intra-arterial delivery of aav vectors to the mouse brain after mannitol mediated blood brain barrier disruption. J. Control. Release 196, 71-78 (2014).
31. Okuma Y, Wang F, Toyoshima A et al. Mannitol enhances therapeutic effects of intra-arterial transplantation of mesenchymal stem cells into the brain after traumatic brain injury. Neurosci. Lett. 554, 156-161 (2013).
32. Joshi S, Ergin A, Wang M et al. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: Implications for chemotherapy. J. Neurooncol. 104(1), 11-19 (2011).
33. Kozler P, Riljak V, Jandova K, Pokorny J. CT imaging and spontaneous behavior analysis after osmotic blood-brain barrier opening in wistar rat. Physiol. Res. 63(Suppl. 4), S529-S534 (2014).
34. Hall WA, Doolittle ND, Daman M et al. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J. Neurooncol. 77(3), 279-284 (2006).
35. Mitragotri S. Devices for overcoming biological barriers: The use of physical forces to disrupt the barriers. Adv. Drug Deliv. Rev. 65(1), 100-103 (2013).
36. Chen H, Konofagou EE. The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure. J. Cereb. Blood Flow Metab. 34(7), 1197-1204 (2014).
37. Sato S, Yoshida K, Kawauchi S et al. Highly site-selective transvascular drug delivery by the use of nanosecond pulsed laser-induced photomechanical waves. J. Control. Release 192, 228-235 (2014).
38. Hearst SM, Walker LR, Shao Q, Lopez M, Raucher D, Vig PJ. The design and delivery of a thermally responsive peptide to inhibit s100b-mediated neurodegeneration. Neuroscience 197, 369-380 (2011).
39. Liu W, Dreher MR, Chow DC, Zalutsky MR, Chilkoti A. Tracking the in vivo fate of recombinant polypeptides by isotopic labeling. J. Control. Release 114(2), 184-192 (2006).
40. Bidwell GL, 3rd, Whittom AA, Thomas E, Lyons D, Hebert MD, Raucher D. A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. Peptides 31(5), 834-841 (2010).
41. Shamji MF, Whitlatch L, Friedman AH, Richardson WJ, Chilkoti A, Setton LA. An injectable and in situ-gelling biopolymer for sustained drug release following perineural administration. Spine (Phila Pa 1976) 33(7), 748-754 (2008).
42. Bidwell GL, 3rd, Perkins E, Hughes J, Khan M, James JR, Raucher D. Thermally targeted delivery of a c-myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS ONE 8(1), e55104 (2013).
43. Urry DW, Parker TM, Reid MC, Gowda DC. Biocompatibility of the bioelastic materials, poly(gvgvp) and its irradiation cross-linked matrix: summary of generic biological test results. Journal of Bioactive and Compatible Polymers 6(3), 263-282 (1991).
44. Toba M, Alzoubi A, O'Neill K et al. A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension. Am. J. Pathol. 184(2), 369-375 (2014).
45. Metildi CA, Felsen CN, Savariar EN et al. Ratiometric activatable cell-penetrating peptides label pancreatic cancer, enabling fluorescence-guided surgery, which reduces metastases and recurrence in orthotopic mouse models. Ann. Surg. Oncol. 22(6), 2082-2087 (2014).
46. Ouahab A, Cheraga N, Onoja V, Shen Y, Tu J. Novel phsensitive charge-reversal cell penetrating peptide conjugated peg-pla micelles for docetaxel delivery: In vitro study. Int. J. Pharm. 466(1-2), 233-245 (2014).
47. Heffernan C, Sumer H, Guillemin GJ, Manuelpillai U, Verma PJ. Design and screening of a glial cell-specific, cell penetrating peptide for therapeutic applications in multiple sclerosis. PLoS ONE 7(9), e45501 (2012).
48. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285(5433), 1569-1572 (1999).
49. Davoli E, Sclip A, Cecchi M et al. Determination of tissue levels of a neuroprotectant drug: the cell permeable jnk inhibitor peptide. J. Pharm. Tox. Meth. 70(1), 55-61 (2014).
50. Rousselle C, Clair P, Temsamani J, Scherrmann JM. Improved brain delivery of benzylpenicillin with a peptidevector-mediated strategy. J. Drug Targ. 10(4), 309-315 (2002).
51. Liu H, Zhang W, Ma L et al. The improved blood-brain barrier permeability of endomorphin-1 using the cellpenetrating peptide synb3 with three different linkages. Int. J. Pharm. 476(1-2), 1-8 (2014).
52. Meloni BP, Craig AJ, Milech N, Hopkins RM, Watt PM, Knuckey NW. The neuroprotective efficacy of cellpenetrating peptides tat, penetratin, arg-9, and pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell. Mol. Neurobiol. 34(2), 173-181 (2014).
53. Wolf Y, Pritz S, Abes S, Bienert M, Lebleu B, Oehlke J. Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides. Biochemistry 45(50), 14944-14954 (2006).
54. Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2(1), 3-14 (2005).
55. Kuo YC, Lee CL. Methylmethacrylatesulfopropylmethacrylate nanoparticles with surface rmp-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. Coll. Surf. B. Biointer. 90, 75-82 (2012).
56. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer. Res. 14(5), 1310-1316 (2008).
57. Lajunen T, Viitala L, Kontturi LS et al. Light induced cytosolic drug delivery from liposomes with gold nanoparticles. J. Control. Release 203C, 85-98 (2015).
58. Knudsen KB, Northeved H, Ek PK et al. Differential toxicological response to positively and negatively charged nanoparticles in the rat brain. Nanotox. 8(7), 764-774 (2014).
59. Au C, Mutkus L, Dobson A, Riffle J, Lalli J, Aschner M. Effects of nanoparticles on the adhesion and cell viability on astrocytes. Biol. Trace Elem. Res. 120(1-3), 248-256 (2007).
60. Kim JS, Yoon TJ, Yu KN et al. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol. Sci. 89(1), 338-347 (2006).
61. Mclennan DN, Porter CJ, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov. Today Technol. 2(1), 89-96 (2005).
62. Dhuria SV, Hanson LR, Frey WH 2nd Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J. Pharm. Sci. 99(4), 1654-1673 (2010).
63. Falcone JA, Salameh TS, Yi X et al. Intranasal administration as a route for drug delivery to the brain: Evidence for a unique pathway for albumin. J. Pharmacol. Exp. Ther. 351(1), 54-60 (2014).
64. Danielyan L, Schafer R, Von Ameln-Mayerhofer A et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of parkinson disease. Rejuv. Res. 14(1), 3-16 (2011).
65. Kanazawa T, Akiyama F, Kakizaki S, Takashima Y, Seta Y. Delivery of sirna to the brain using a combination of nose-tobrain delivery and cell-penetrating peptide-modified nanomicelles. Biomaterials 34(36), 9220-9226 (2013).
66. Walker LR, Ryu JS, Perkins E, Mcnally LR, Raucher D. Fusion of cell-penetrating peptides to thermally responsive biopolymer improves tumor accumulation of p21 peptide in a mouse model of pancreatic cancer. Drug Des. Devel. Ther. 8, 1649-1658 (2014).
67. Sun Z, Worden M, Wroczynskyj Y et al. Magnetic field enhanced convective diffusion of iron oxide nanoparticles in an osmotically disrupted cell culture model of the blood-brain barrier. Int. J. Nanomed. 9, 3013-3026 (2014).
68. Li J, Zhang C, Fan L et al. Brain delivery of nap with pegplga nanoparticles modified with phage display peptides. Pharm. Res. 30(7), 1813-1823 (2013).